Biotech & Pharma

Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease

22 sec read53 views0 listens

Biotech company Moonwalk Biosciences has raised $70 million to develop RNA interference (RNAi) therapies targeting obesity and cardiometabolic diseases. This funding will advance its lead candidate, MW101, into clinical trials by late 2027 and expand research on siRNA medicines, offering potential new treatments for these conditions.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

AI & Machine LearningSep 923 sec read

Man Announces That He Has Synthesized a New Schizophrenia Treatment in His Garage, Based on a Formula Devised by ChatGPT

A biochemist named Douglas Yao has synthesized a potential schizophrenia treatment called PAC-3310 in his garage, using a formula devised by AI model ChatGPT. This development highlights the growing role of AI in drug discovery but raises significant...

Ali Nemati

Biotech & PharmaSep 431 sec read

Cancer Drug Reduces SIV Reservoir in Macaques, May Inform HIV Cure Strategies

Researchers at Emory University found that venetoclax, a cancer drug, reduced the SIV reservoir in macaques when administered alongside antiretroviral therapy. This discovery could inform strategies to eliminate HIV's latent viral reservoir, advancin...

Ali Nemati

CybersecurityAug 2627 sec read

Canadian supercomputers are transforming drug discovery: Can they deliver medicines faster?

Researchers at Simon Fraser University have developed an AI framework called CGFlow, which accelerates the design of drug molecules by ensuring they can be synthesized in a laboratory. This advancement is crucial for reducing the time and cost associ...

Ali Nemati